Drug Approval | December 06, 2023
Granules India received ANDA approval for Sildenafil for oral suspension
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
The product will be manufactured at Lupin’s Nagpur facility in India
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Subscribe To Our Newsletter & Stay Updated
